| FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $380.81M | ||||
Company | Location |
Date | Amt. (M) |
Details |
ARCA |
Denver |
3/2/06 |
$15 |
The Series A financing was led by Atlas Venture, and included seed investor Boulder Ventures and Pequot Capital Management |
APT |
Tucson, Ariz. |
3/21/06 |
$3 |
Vivo Ventures participated in the final close of a $9 million Series A round; APT raised $6M in the first close in July 2005 |
AVEO |
Cambridge, Mass. |
3/30/06 |
$15 |
Hercules Technology Growth Capital Inc. provided $15M in debt financing to AVEO |
AxoGen Inc. |
Gainesville, Fla. |
3/9/06 |
$7.75 |
The Series B financing round was led by Cardinal Partners, Accuitive Medical Ventures and De Novo Ventures |
BioTrove |
Woburn, Mass. |
3/8/06 |
$15 |
Investing in the financing round, part of which closed in 2005, were Catalyst Health and Technology Partners, Echelon Ventures, Fletcher Spaght and CB Health Ventures |
BioXell SpA |
Milan, Italy |
3/15/06 |
€10.5 ($12.8) |
The deal marked an extension of a Series C financing, the first part of which brought in €23M in October 2004; TVM Capital led the extension, which also included BB Biotech, Index Ventures and Life Science Partners |
Chronogen |
Montreal |
3/28/06 |
$3.28 |
MMV Financial Inc. provided a venture loan to the company |
Covalys |
Witterswil, Switzerland |
3/2/06 |
ND |
Participating in the Series C financing were existing investors BVgroup Private Equity, Novartis Venture Fund and Venture Incubator |
Egalet A/S |
Copenhagen, Denmark |
3/13/06 |
$27.6 |
The financing was led by new investors Atlas Venture and Index Ventures and included existing investors Bio Fund, Dansk Kapitalanlaeg, Danske Bank and QueQuoin Holdings Ltd. |
Evogene Ltd. |
Rehovat, Israel |
3/1/06 |
$5.25 |
The Series B financing totaled $7M; the first $1.75M of the round came in May 2005 through a convertible bridge loan |
F2G Ltd. |
Manchester, UK |
3/22/06 |
£5 ($8.7) |
The funding was led by BankInvest and included new investor Astellas Venture Management LLC |
Genizon BioSciences |
Montreal |
3/29/06 |
$12.4 |
Investors in the convertible debenture financing included HBM Bioventures, Biofund Management, MVI Finance, Carnegie, Genizon officials and employees, and Illumina Inc. (3/29) |
Helicos |
Cambridge, Mass. |
3/15/06 |
$40 |
The Series B financing was provided by existing investors Flagship Ventures, Atlas Ventures, Highland Capital, MPM Capital and Versant Ventures |
InfaCare |
Plymouth Meeting, Pa. |
3/10/06 |
$30 |
The Series A financing was co-led by new investors Atlas Venture and Pequot Ventures; Leerink Swann & Co. was placement agent |
Intrexon |
Blacksburg, Va. |
3/1/06 |
$1 |
The financing was provided by NewVa Capital Partners LP |
IRX |
New York |
3/22/06 |
$12.5 |
The funding was provided in the form of a convertible note offering |
Motif |
New York |
3/2/06 |
$1.88 |
Amphion Innovations plc led the financing round and now holds a stake of about 47% in Motif |
NanoCarrier |
Chiba, Japan |
3/30/06 |
Y400M ($3.4) |
Among the investors in the mezzanine funding round were partner Debiopharm SA |
Nereus |
San Diego |
3/6/06 |
$18.3 |
Nereus raised $18.3M in the second tranche of its Series D round; $24.3M was raised in the first tranche in December 2004; lead investors were HBM BioVentures Ltd. and HBM BioCapital LP; other continuing Series D investors included Alta Partners, Forward Ventures, Pacific Venture Group, Novartis Bioventure Fund, Genavent Partners, Lotus BioScience Ventures, FirstBio, InterWest Partners, Red Abbey Venture Partners, Advent International and GIMV |
Neuralstem |
Rockville, Md. |
3/13/06 |
$5 |
TR Winston & Co. was placement agent in the financing, with participation from S W Bach & Co. |
Neuromed |
Vancouver, British Columbia |
3/8/06 |
$25 |
Participating in the Series D financing were existing investors MPM Capital, Neuro Discovery LP, GrowthWorks Capital, CMDF, BDC Venture Capital, Cogene Biotech Ventures and the Royal Bank of Canada and new investor James Richardson & Sons Ltd. |
NuGEN |
San Carlos, Calif. |
3/21/06 |
$7.75 |
The financing round was led by Alloy Ventures and included existing investors Sutter Hill Ventures, Radius Ventures and The Band of Angels |
PanGenetics |
Utrecht, the Netherlands |
3/27/06 |
€13 ($15.8) |
The Series B financing was led by ABN AMRO Capital and included Crédit Agricole Private Equity and seed investor Index Ventures |
Proteon |
Kansas City, Mo. |
3/30/06 |
$19 |
TVM Capital and Skyline Ventures co-led the Series A financing round, which also included Prism Venture Partners and Intersouth Partners |
Psynova Ltd. |
Cambridge, UK |
3/16/06 |
£2.25 ($3.9) |
Investors in the Series A financing for the Cambridge University spin-off were Porton Capital and Cambridge Enterprise |
Santaris |
Copenhagen, Denmark |
3/15/06 |
€40 ($48.5) |
The Series B financing was led by ABN AMRO Capital Life Sciences and included Global Life Science Ventures, Vaekstfonden and SPEF Venture, which together provided about half the funding; existing investors provided the other half |
7TM Pharma |
Horsholm, Denmark |
3/31/06 |
€19 ($23) |
The Series C financing round was led by LD Pensions in collaboration with Scottish Widows Investment Partnership and included existing investors Alta Partners, Novo A/S, Index Ventures, Johnson & Johnson Development Corp. and Dansk Innovations investering |
Notes: | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
ND = Not disclosed. | ||||
To read more on related topics, click on one of the words below.